[go: up one dir, main page]

MXPA02004556A - Soluciones que contienen epinastina. - Google Patents

Soluciones que contienen epinastina.

Info

Publication number
MXPA02004556A
MXPA02004556A MXPA02004556A MXPA02004556A MXPA02004556A MX PA02004556 A MXPA02004556 A MX PA02004556A MX PA02004556 A MXPA02004556 A MX PA02004556A MX PA02004556 A MXPA02004556 A MX PA02004556A MX PA02004556 A MXPA02004556 A MX PA02004556A
Authority
MX
Mexico
Prior art keywords
solutions containing
containing epinastine
epinastine
racemate
enantiomers
Prior art date
Application number
MXPA02004556A
Other languages
English (en)
Inventor
Duschler Gerold
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7928843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02004556(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MXPA02004556A publication Critical patent/MXPA02004556A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01L—CYCLICALLY OPERATING VALVES FOR MACHINES OR ENGINES
    • F01L9/00—Valve-gear or valve arrangements actuated non-mechanically
    • F01L9/20—Valve-gear or valve arrangements actuated non-mechanically by electric means
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T137/00—Fluid handling
    • Y10T137/0318—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Detergent Compositions (AREA)

Abstract

La invencion se refiere a soluciones acuosas aplicables por via topica que contienen epinastina, eventualmente en forma de sus racematos, sus enantiomeros, asi como eventualmente en forma de sus sales por adicion de acidos farcmacologicamente inocuas.
MXPA02004556A 1999-11-12 2000-10-14 Soluciones que contienen epinastina. MXPA02004556A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19954516A DE19954516A1 (de) 1999-11-12 1999-11-12 Epinastin-haltige Lösungen
PCT/EP2000/010122 WO2001035962A1 (de) 1999-11-12 2000-10-14 Epinastin-haltige lösungen

Publications (1)

Publication Number Publication Date
MXPA02004556A true MXPA02004556A (es) 2004-09-10

Family

ID=7928843

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02004556A MXPA02004556A (es) 1999-11-12 2000-10-14 Soluciones que contienen epinastina.

Country Status (40)

Country Link
US (6) US20030050303A1 (es)
EP (1) EP1231920B1 (es)
JP (1) JP2003514021A (es)
KR (1) KR100758842B1 (es)
CN (1) CN1292752C (es)
AR (1) AR026424A1 (es)
AT (1) ATE353218T1 (es)
AU (2) AU784017B2 (es)
BG (1) BG65775B1 (es)
BR (1) BR0015477A (es)
CA (1) CA2391076C (es)
CO (1) CO5251448A1 (es)
CY (1) CY1106375T1 (es)
CZ (1) CZ302483B6 (es)
DE (2) DE19954516A1 (es)
DK (1) DK1231920T3 (es)
EA (1) EA006937B1 (es)
EE (1) EE05395B1 (es)
ES (1) ES2281359T3 (es)
HK (1) HK1052303B (es)
HR (1) HRP20020404B1 (es)
HU (1) HU229502B1 (es)
IL (2) IL149501A0 (es)
ME (1) MEP36708A (es)
MX (1) MXPA02004556A (es)
MY (1) MY130441A (es)
NO (1) NO329417B1 (es)
NZ (1) NZ519425A (es)
PE (1) PE20010826A1 (es)
PL (1) PL198879B1 (es)
PT (1) PT1231920E (es)
RS (1) RS50173B (es)
SA (1) SA01210658B1 (es)
SI (1) SI1231920T1 (es)
SK (1) SK287343B6 (es)
TR (1) TR200201270T2 (es)
TW (1) TWI225401B (es)
UA (1) UA74563C2 (es)
WO (1) WO2001035962A1 (es)
ZA (1) ZA200203683B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
CA2494065A1 (en) * 2002-08-02 2004-02-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulations comprising combinations of epinastine, pseudoephedrine and methylephedrine
US20040247686A1 (en) * 2003-04-04 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
EP1468696A1 (en) * 2003-04-17 2004-10-20 Boehringer Ingelheim International GmbH Combinations of epinastine and antiphlogisitcs as new pharmaceutical compositions for the treatment of skin diseases
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
US20090143359A1 (en) * 2005-07-08 2009-06-04 Akiharu Isowaki Percutaneously Absorptive Ophthalmic Preparation Comprising Epinastine
US7378082B1 (en) 2007-11-05 2008-05-27 Inspire Pharmaceuticals, Inc. Method for treating allergic rhinitis without adverse effects
WO2008098122A2 (en) * 2007-02-08 2008-08-14 Inspire Pharmaceuticals, Inc. Method for treating allergic rhinitis without adverse effects
US20080194544A1 (en) * 2007-02-08 2008-08-14 Ramesh Krishnamoorthy Aqueous formulations of epinastine for treating allergic rhinitis
EP2464387A4 (en) * 2009-08-12 2013-05-15 Seros Medical Llc DEUTERATED WATER SOLUTION AND RIBOFLAVIN FOR EXTENDED OXYGEN SINGULET LIFETIME IN THE TREATMENT OF OCULAR TISSUE AND METHOD OF USE
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
EP2630952A1 (en) * 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
EP3827823A1 (en) * 2012-12-19 2021-06-02 Novartis AG Lfa-1 inhibitor formulations
CN104491876A (zh) * 2014-12-23 2015-04-08 中国药科大学 含玻璃酸钠的依匹斯汀滴眼液及其制备方法
ITUB20153950A1 (it) * 2015-09-28 2017-03-28 Tred Srl Dispositivo nasale in grado di attivare il riflesso rino-palatale per l'igienizzazione rinofaringea
JP6134853B1 (ja) * 2016-10-28 2017-05-24 参天製薬株式会社 エピナスチン含有点眼液
JP6635974B2 (ja) * 2017-04-24 2020-01-29 参天製薬株式会社 エピナスチン含有点眼液
KR102766744B1 (ko) * 2017-05-01 2025-02-11 산텐 세이야꾸 가부시키가이샤 점안제
JP2019108320A (ja) * 2018-10-31 2019-07-04 参天製薬株式会社 ソフトコンタクトレンズの変質を抑制する眼科用組成物
JP7599838B2 (ja) * 2019-04-10 2024-12-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性医薬組成物
JP6736752B2 (ja) * 2019-12-17 2020-08-05 参天製薬株式会社 エピナスチン含有点眼液
JP7118579B1 (ja) 2020-04-16 2022-08-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性組成物
JP6963651B2 (ja) * 2020-04-16 2021-11-10 参天製薬株式会社 エピナスチン又はその塩を含有する水性組成物
JP2020169213A (ja) * 2020-07-15 2020-10-15 参天製薬株式会社 エピナスチン含有点眼液
JP7114668B2 (ja) * 2020-10-08 2022-08-08 参天製薬株式会社 エピナスチン又はその塩を含有する花粉破裂抑制剤
CN115448927A (zh) * 2022-10-20 2022-12-09 重庆瑞泊莱医药科技有限公司 一种氢溴酸依匹斯汀晶型ii及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US215396A (en) * 1879-05-13 Improvement in loom-temples
US8632A (en) * 1852-01-06 George hess
US181478A (en) * 1876-08-22 Improvement in water-wheels
US203021A (en) * 1878-04-30 Improvement in side-bar wagons
US228359A (en) * 1880-06-01 jones
US104017A (en) * 1870-06-07 Improvement in embroidering attachment for sewing-machines
US151541A (en) * 1874-06-02 Improvement in hay-loaders
DE3008944A1 (de) * 1980-03-08 1981-09-24 C.H. Boehringer Sohn, 6507 Ingelheim Dibenzimidazoazepine, ihre herstellung und verwendung
DE4102148A1 (de) * 1991-01-25 1992-07-30 Boehringer Ingelheim Kg Verfahren zur herstellung von 3-amino-9,13b-dihydro-1h-dibenz-(c,f)imidazol(1,5-a)azepin-hydrochlorid
US5668133A (en) * 1992-12-09 1997-09-16 Alcon Laboratories, Inc. Ophthalmic compositions comprising emedastine and methods for their use
MX9800125A (es) * 1995-06-27 1998-03-31 Boehringer Ingelheim Kg Nuevas composiciones medicinales estables para generar aerosoles libres de gas propulsor.
DE19542281C2 (de) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
US6201011B1 (en) * 1996-08-30 2001-03-13 Kyoto Pharmaceutical Industries, Ltd. Therapeutic agent for allergic dermatitis
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US20030215396A1 (en) * 1999-09-15 2003-11-20 Boehringer Ingelheim Pharma Kg Method for the production of propellant gas-free aerosols from aqueous medicament preparations
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
WO2001035963A1 (en) * 1999-11-18 2001-05-25 Alcon Universal Ltd. Use of h1 antagonist and a safe steroid to treat eye conditions
DE19958460A1 (de) * 1999-12-03 2001-06-07 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Epinastine-Hydrochlorid in der hochschmelzenden Kristallmodifikation
FR2803520B1 (fr) * 2000-01-12 2002-09-20 Ceva Sante Animale Procede pour augmenter la production d'oeufs et consolider la coquille des oeufs chez les volailles
US20020094345A1 (en) * 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
DE10119718A1 (de) * 2001-04-21 2002-10-31 Boehringer Ingelheim Pharma Verfahren zur kontinuierlichen Herstellung inhalierfähiger Arzneistoffe, Vorrichtung zur Durchführung des Verfahrens und nach diesem Verfahren hergestellter Arzneistoff
AU2002305780A1 (en) * 2001-05-29 2002-12-09 Transchip, Inc. Patent application cmos imager for cellular applications and methods of using such
US20030104017A1 (en) * 2001-10-26 2003-06-05 Boehringer Ingelheim International Gmbh Epinastine formulation for oral administration
EP1350512A1 (en) * 2002-04-03 2003-10-08 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations
US6863848B2 (en) * 2002-08-30 2005-03-08 Signet Armorlite, Inc. Methods for preparing composite photochromic ophthalmic lenses
JP2007145316A (ja) * 2005-10-27 2007-06-14 Nissan Motor Co Ltd 遮光装置とサンバイザーとサンルーフユニット

Also Published As

Publication number Publication date
CN1390129A (zh) 2003-01-08
BG65775B1 (bg) 2009-11-30
CZ20021956A3 (cs) 2002-08-14
US20070185082A1 (en) 2007-08-09
IL149501A (en) 2012-04-30
YU33602A (sh) 2005-03-15
HU229502B1 (en) 2014-01-28
EE200200246A (et) 2003-06-16
PT1231920E (pt) 2007-03-30
HRP20020404B1 (hr) 2007-08-31
PL198879B1 (pl) 2008-07-31
CO5251448A1 (es) 2003-02-28
KR100758842B1 (ko) 2007-09-19
US20090239842A1 (en) 2009-09-24
EP1231920A1 (de) 2002-08-21
SI1231920T1 (sl) 2007-06-30
ES2281359T3 (es) 2007-10-01
AR026424A1 (es) 2003-02-12
HRP20020404A2 (en) 2004-08-31
HUP0203773A2 (hu) 2003-03-28
PL364028A1 (en) 2004-11-29
SK8302002A3 (en) 2002-09-10
PE20010826A1 (es) 2001-08-20
TR200201270T2 (tr) 2002-12-23
HUP0203773A3 (en) 2005-01-28
MY130441A (en) 2007-06-29
CN1292752C (zh) 2007-01-03
NO20022201L (no) 2002-05-08
EA006937B1 (ru) 2006-06-30
US7429602B2 (en) 2008-09-30
US20080009476A1 (en) 2008-01-10
HK1052303A1 (en) 2003-09-11
EP1231920B1 (de) 2007-02-07
DE19954516A1 (de) 2001-05-17
HK1052303B (zh) 2007-04-13
CZ302483B6 (cs) 2011-06-08
CA2391076A1 (en) 2001-05-25
WO2001035962A1 (de) 2001-05-25
DE50014041D1 (de) 2007-03-22
AU784017B2 (en) 2006-01-12
BG106681A (en) 2002-12-29
BR0015477A (pt) 2002-06-25
CA2391076C (en) 2008-06-17
MEP36708A (en) 2011-02-10
DK1231920T3 (da) 2007-04-10
ZA200203683B (en) 2003-09-03
AU1138101A (en) 2001-05-30
JP2003514021A (ja) 2003-04-15
RS50173B (sr) 2009-05-06
UA74563C2 (uk) 2006-01-16
EA200200492A1 (ru) 2002-10-31
IL149501A0 (en) 2002-11-10
NO329417B1 (no) 2010-10-18
US20030050303A1 (en) 2003-03-13
NO20022201D0 (no) 2002-05-08
TWI225401B (en) 2004-12-21
SK287343B6 (sk) 2010-07-07
CY1106375T1 (el) 2011-10-12
NZ519425A (en) 2004-04-30
EE05395B1 (et) 2011-04-15
US20050288274A1 (en) 2005-12-29
US20070197503A1 (en) 2007-08-23
ATE353218T1 (de) 2007-02-15
KR20020050273A (ko) 2002-06-26
SA01210658B1 (ar) 2006-11-05
AU2006201541A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
MXPA02004556A (es) Soluciones que contienen epinastina.
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
ATE304346T1 (de) Zink enthaltende zahnpasta zusammensetzungen
MXPA03000510A (es) Sales estables de acido o-acetilsalicilico con aminoacidos basicos.
BG111461A (en) TECHNICAL METHOD FOR OBTAINING TROPENOL
BR0013417B1 (pt) composiÇço aquosa.
PL369304A1 (en) Toilet bar having a latent acidifier
WO2002030870A3 (de) Substituierte c-cyclohexylmethylamin-derivate
BG105689A (en) Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia
CA2362698A1 (en) Resorcinol derivatives
WO2002068575A8 (en) Liquid detergent composition exhibiting enhanced α-amylase enzyme stability
EA200101150A1 (ru) Раствор прукалоприда для перорального применения
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
AU3214100A (en) Liquid descaling composition
ZA200305877B (en) Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof.
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
WO2002076376A3 (en) A stable pharmaceutical composition of pravastatin
EP1219296A4 (en) MEANS TO INHIBIT SEBUM PRODUCTION
IL147023A0 (en) Stable xylometazoline and oxymetazoline solution
ATE294154T1 (de) Apfelsäureadditionssalze von terbinafin
AU2912300A (en) Peroxochloric acid, derivatives and anions, salts thereof, method for producing them and use of the same
MXPA04002640A (es) Esteres de analogos de 3-desoxi-vitamina d3.
WO2001055198A3 (de) Haut- und magen-spezifischer sphingolipid-aktivator
AU3661500A (en) Method for the production of 4'-demethyl - 4'-phosphate-2",3" - bis pentafluorophenoxyacetyl 4",6"-ethylidene - beta-d- glucoside epipodophyllotoxin and the salts thereof
NO20040423L (no) Salter av substituerte 1,2,3,4-tetrahydroisokinolin-2-karboksylsyrederivater.

Legal Events

Date Code Title Description
FG Grant or registration